ftc report pharmacy benefit managers

Pharmacy managers inflated drug prices by $7.3 billion

FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

Reuters · 1d

US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain

The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies, the U.S.

The Financial Times · 1d

FTC says pharmacy benefits managers marked-up generic drug prices for $7.3bn gain

Regulator’s report finds companies ‘hiked costs’ for a range of medicines, including cancer and HIV treatments

1don MSN

Largest Pharmacy-Benefit Managers Hiked Up Drug Prices, FTC Says

The largest pharmacy-benefit managers hiked the prices of dozens of drugs dispensed through their own pharmacies, according ...

ConsumerAffairs23h

Another FTC report is highly critical of pharmacy benefit managers

In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...

Healthcare Dive1d

FTC releases second report slamming pharmacy benefit managers

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...

pharmaphorum23h

FTC doubles down on PBM criticism in new report

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

KITV16h

Pharmacy benefit managers marked up drug prices by $7.3B, new reports finds

A new FTC report blames Pharmacy Benefit Managers for marking up specialty drug prices, profiting $7.3 billion from cancer and HIV treatments between 2017-2022.

policymed.com21h

Second Federal Trade Commission Report on Pharmacy Benefit Managers (PBM’s) Focuses on Specialty Generics

The Federal Trade Commission (FTC) released its second interim staff report “Specialty Generic Drugs a Growing Profit Center ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results